| Zugriffsnummer | 50836 |
| Dokumenttyp | Zeitschriftenartikel |
| Peer Review | mit Peer Review |
| Sprache | Englisch |
| Titel | Independent contribution of polygenic risk for schizophrenia and cannabis use in predicting psychotic-like experiences in young adulthood: testing gene × environment moderation and mediation |
| Autor(in); Institution |
Elkrief, L.; Sainte-Justine Hospital Research Center, Montréal, Québec, CANADA; Département de psychiatrie et d'addictologie, Université de Montréal, Montréal, QC, CANADA
Lin, B.; Department of Translational Neuroscience, Brain Center University Medical Center, Utrecht University, Utrecht, THE NETHERLANDS
Marchi, M.; Department Psychiatry, Brain Center University Medical Center Utrecht, Utrecht, THE NETHERLANDS; Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Via Giuseppe Campi, Modena, ITALY
Afzali, M.; Sainte-Justine Hospital Research Center, Montréal, Québec, CANADA; Département de psychiatrie et d'addictologie, Université de Montréal, Montréal, QC, CANADA
Banaschewski, T.; Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, GERMANY
Bokde, A.; Discipline of Psychiatry, School of Medicine and Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, IRELAND
Quinlan, E.; Centre for Population Neuroscience and Precision Medicine (PONS), Institute of Psychiatry, Psychology & Neuroscience, SGDP Centre, King's College London, UK
Desrivières, S.; Centre for Population Neuroscience and Precision Medicine (PONS), Institute of Psychiatry, Psychology & Neuroscience, SGDP Centre, King's College London, UK
Flor, H.; Department of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, GERMANY; Department of Psychology, School of Social Sciences, University of Mannheim, Mannheim, GERMANY
Garavan, H.; Departments of Psychiatry and Psychology, University of Vermont, Burlington, Vermont, USA
Gowland, P.; Sir Peter Mansfield Imaging Centre School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, UK
Heinz, A.; Charité - Universitätsmedizin Berlin, Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Berlin, GERMANY
Martinot, J.; Institut National de la Santé et de la Recherche Médicale, INSERM Unit 1000 "Neuroimaging & Psychiatry", University Paris Saclay, University Paris Descartes - Sorbonne Paris Cité; and Maison de Solenn, Paris, FRANCE
Martinot, M.; Institut National de la Santé et de la Recherche Médicale, INSERM Unit 1000 "Neuroimaging & Psychiatry", University Paris Sud, University Paris Descartes; and AP-HP.Sorbonne Université, Department of Child and Adolescent Psychiatry, Pitié-Salpêtrière Hospital, Paris, FRANCE
Nees, F.; Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, GERMANY; Department of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, GERMANY
Orfanos, D.; NeuroSpin, CEA, Université Paris-Saclay, Gif-sur-Yvette, FRANCE
Paus, T.; Bloorview Research Institute, Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, CANADA
Poustka, L.; Department of Child and Adolescent Psychiatry and Psychotherapy, University Medical Centre Göttingen, Göttingen, GERMANY
Hohmann, S.; Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, GERMANY
Fröhner, J.; Department of Psychiatry and Neuroimaging Center, Technische Universität Dresden, Dresden, GERMANY
Smolka, M.; Department of Psychiatry and Neuroimaging Center, Technische Universität Dresden, Dresden, GERMANY
Walter, H.; Charité - Universitätsmedizin Berlin, Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Berlin, GERMANY
Whelan, R.; School of Psychology and Global Brain Health Institute, Trinity College Dublin, IRELAND
Schumann, G.; Centre for Population Neuroscience and Precision Medicine (PONS), Institute of Psychiatry, Psychology & Neuroscience, SGDP Centre, King's College London, UK; School of Psychology and Global Brain Health Institute, Trinity College Dublin, IRELAND; PONS Research Group, Dept of Psychiatry and Psychotherapy, Campus Charite Mitte, Humboldt University, Berlin and Leibniz Institute for Neurobiology, Magdeburg, GERMANY
Luykz, J.; Department Psychiatry, Brain Center University Medical Center Utrecht, Utrecht, THE NETHERLANDS
Boks, M.; Department Psychiatry, Brain Center University Medical Center Utrecht, Utrecht, THE NETHERLANDS
Conrod, P.; Sainte-Justine Hospital Research Center, Montréal, Québec, CANADA; Département de psychiatrie et d'addictologie, Université de Montréal, Montréal, QC, CANADA
IMAGEN consortium,
|
| Quelle/Jahr | Psychological Medicine: 53 (2023), 4, 1759 - 1769 |
| ISSN | 0033-2917 (print) ; 1469-8978 (online) |
| DOI | |
| Verlag | Cambridge: Cambridge University Press |
| Freie Schlagworte | Polygenic risk score ; cannabis ; psychosis risk ; psychotic-like experience |
| Zusammenfassung | Background: It has not yet been determined if the commonly reported cannabis-psychosis association is limited to individuals with pre-existing genetic risk for psychotic disorders. Methods: We examined whether the relationship between polygenic risk score for schizophrenia (PRS-Sz) and psychotic-like experiences (PLEs), as measured by the Community Assessment of Psychic Experiences-42 (CAPE-42) questionnaire, is mediated or moderated by lifetime cannabis use at 16 years of age in 1740 of the individuals of the European IMAGEN cohort. Secondary analysis examined the relationships between lifetime cannabis use, PRS-Sz and the various sub-scales of the CAPE-42. Sensitivity analyses including covariates, including a PRS for cannabis use, were conducted and results were replicated using data from 1223 individuals in the Dutch Utrecht cannabis cohort. Results: PRS-Sz significantly predicted cannabis use (p = 0.027) and PLE (p = 0.004) in the IMAGEN cohort. In the full model, considering PRS-Sz and covariates, cannabis use was also significantly associated with PLE in IMAGEN (p = 0.007). Results remained consistent in the Utrecht cohort and through sensitivity analyses. Nevertheless, there was no evidence of a mediation or moderation effects. Conclusions: These results suggest that cannabis use remains a risk factor for PLEs, over and above genetic vulnerability for schizophrenia. This research does not support the notion that the cannabis-psychosis link is limited to individuals who are genetically predisposed to psychosis and suggests a need for research focusing on cannabis-related processes in psychosis that cannot be explained by genetic vulnerability. |
| Kostenfreier Zugang | Open Access Hybrid |
| Rechteinformation | CC BY 4.0 ; Creative Commons Attribution 4.0 License |
| Themenbereich der Metrologie | Metrologie in der Medizin |
Zitierung
Elkrief, L., Lin, B., Marchi, M., Afzali, M., Banaschewski, T., Bokde, A., Quinlan, E., Desrivières, S., Flor, H., Garavan, H., Gowland, P., Heinz, A., Ittermann, B., Martinot, J., Martinot, M., Nees, F., Orfanos, D., Paus, T., Poustka, L., Hohmann, S., Fröhner, J., Smolka, M., Walter, H., Whelan, R., Schumann, G., Luykz, J., Boks, M., Conrod, P., & IMAGEN consortium. (2023). Independent contribution of polygenic risk for schizophrenia and cannabis use in predicting psychotic-like experiences in young adulthood: testing gene × environment moderation and mediation. Psychological Medicine, 53(4), 1759–1769. https://doi.org/10.1017/S0033291721003378